Upstream Bio, Inc. UPB shares were trading higher during Wednesday’s premarket session following positive results from the Phase 2 VALIANT trial of verekitug, a treatment for severe asthma. The stock ...
Upstream Bio has sailed to a phase 2 win in sinusitis and plans to push its candidate forward against a competitive current. Investigators randomized 81 adults with chronic rhinosinusitis with nasal ...
Investor's Business Daily on MSN
Upstream Bio crashes after asthma drug succeeds — with the wrong dose
Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen.
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results